JP2018528258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528258A5 JP2018528258A5 JP2018521475A JP2018521475A JP2018528258A5 JP 2018528258 A5 JP2018528258 A5 JP 2018528258A5 JP 2018521475 A JP2018521475 A JP 2018521475A JP 2018521475 A JP2018521475 A JP 2018521475A JP 2018528258 A5 JP2018528258 A5 JP 2018528258A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- pharmaceutical composition
- organ
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192269P | 2015-07-14 | 2015-07-14 | |
| US62/192,269 | 2015-07-14 | ||
| US201562197966P | 2015-07-28 | 2015-07-28 | |
| US62/197,966 | 2015-07-28 | ||
| US201662277201P | 2016-01-11 | 2016-01-11 | |
| US62/277,201 | 2016-01-11 | ||
| PCT/US2016/042074 WO2017011544A1 (en) | 2015-07-14 | 2016-07-13 | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021003152A Division JP2021063129A (ja) | 2015-07-14 | 2021-01-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528258A JP2018528258A (ja) | 2018-09-27 |
| JP2018528258A5 true JP2018528258A5 (enExample) | 2019-08-15 |
| JP6826113B2 JP6826113B2 (ja) | 2021-02-03 |
Family
ID=57757587
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521475A Active JP6826113B2 (ja) | 2015-07-14 | 2016-07-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2021003152A Pending JP2021063129A (ja) | 2015-07-14 | 2021-01-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2023110414A Active JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A Pending JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021003152A Pending JP2021063129A (ja) | 2015-07-14 | 2021-01-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2023110414A Active JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A Pending JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10874738B2 (enExample) |
| EP (2) | EP3331548B1 (enExample) |
| JP (4) | JP6826113B2 (enExample) |
| KR (2) | KR102825142B1 (enExample) |
| CN (2) | CN114671952A (enExample) |
| AU (3) | AU2016294417B2 (enExample) |
| CL (1) | CL2018000103A1 (enExample) |
| CO (1) | CO2018001363A2 (enExample) |
| CR (1) | CR20180097A (enExample) |
| DO (1) | DOP2018000018A (enExample) |
| EA (1) | EA201890297A1 (enExample) |
| EC (1) | ECSP18009949A (enExample) |
| GT (1) | GT201800018A (enExample) |
| HK (1) | HK1249735A1 (enExample) |
| IL (3) | IL310460A (enExample) |
| MX (2) | MX2018000548A (enExample) |
| MY (2) | MY196991A (enExample) |
| PE (1) | PE20180741A1 (enExample) |
| PH (1) | PH12018500098A1 (enExample) |
| SG (1) | SG10201913431QA (enExample) |
| TN (1) | TN2018000021A1 (enExample) |
| WO (1) | WO2017011544A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201890297A1 (ru) * | 2015-07-14 | 2018-06-29 | Иммьюнекст, Инк. | Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека |
| CN108473561B (zh) | 2015-11-27 | 2022-12-16 | 埃博灵克斯股份有限公司 | 抑制cd40l的多肽 |
| US11505610B2 (en) | 2018-04-06 | 2022-11-22 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| WO2020056162A1 (en) * | 2018-09-12 | 2020-03-19 | Oregon Health & Science University | Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival |
| WO2020068723A1 (en) * | 2018-09-24 | 2020-04-02 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| CN115227824A (zh) * | 2018-11-12 | 2022-10-25 | 中南大学湘雅二医院 | 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用 |
| CN114173772A (zh) * | 2019-04-12 | 2022-03-11 | 托尼克斯医药控股公司 | Cd40-cd154结合的抑制剂 |
| CN114746120B (zh) | 2019-10-03 | 2024-07-30 | Atyr医药公司 | 包含抗nrp2抗体的组合物和方法 |
| CN113488170B (zh) * | 2021-07-02 | 2023-07-25 | 温州医科大学 | 急性前葡萄膜炎复发风险预测模型构建方法及相关设备 |
| EP4382537A4 (en) * | 2021-07-30 | 2025-07-23 | Seoul Nat Univ R&Db Foundation | ANTI-CD154 ANTIBODY AND ITS USE |
| WO2023008982A1 (ko) * | 2021-07-30 | 2023-02-02 | 서울대학교산학협력단 | 항 cd154 항체 및 이의 용도 |
| EP4688856A1 (en) | 2023-04-03 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| AU2024262779A1 (en) | 2023-04-28 | 2025-12-11 | Fortvita Biologics Inc. | Anti-cd40l antibody and use thereof in treatment of human autoimmune diseases |
| US20240392022A1 (en) * | 2023-05-22 | 2024-11-28 | Genzyme Corporation | Treatment of multiple sclerosis with anti-cd40l antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995006666A1 (en) | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Anti-gp39 antibodies and uses therefor |
| US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6444018B1 (en) | 1998-06-25 | 2002-09-03 | Xerox Corporation | Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts |
| GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| TR200300478T2 (tr) | 2000-10-13 | 2004-10-21 | Biogen Inc. | Hümanize antiLT-ß-R antikorları |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| DE602004029252D1 (de) * | 2003-06-13 | 2010-11-04 | Biogen Idec Inc | Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| WO2006104989A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| SG196697A1 (en) * | 2007-03-22 | 2014-02-13 | Biogen Idec Inc | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| WO2012138768A2 (en) * | 2011-04-04 | 2012-10-11 | Trustees Of Dartmouth College | Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies |
| US9321833B2 (en) * | 2011-04-04 | 2016-04-26 | The Trustees Of Dartmouth College | Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| EA201890297A1 (ru) * | 2015-07-14 | 2018-06-29 | Иммьюнекст, Инк. | Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека |
-
2016
- 2016-07-13 EA EA201890297A patent/EA201890297A1/ru unknown
- 2016-07-13 HK HK18109202.5A patent/HK1249735A1/zh unknown
- 2016-07-13 EP EP16825103.1A patent/EP3331548B1/en active Active
- 2016-07-13 MX MX2018000548A patent/MX2018000548A/es unknown
- 2016-07-13 IL IL310460A patent/IL310460A/en unknown
- 2016-07-13 JP JP2018521475A patent/JP6826113B2/ja active Active
- 2016-07-13 CN CN202210146798.5A patent/CN114671952A/zh active Pending
- 2016-07-13 MY MYPI2018700104A patent/MY196991A/en unknown
- 2016-07-13 CN CN201680053004.3A patent/CN108135969B/zh active Active
- 2016-07-13 WO PCT/US2016/042074 patent/WO2017011544A1/en not_active Ceased
- 2016-07-13 US US15/744,379 patent/US10874738B2/en active Active
- 2016-07-13 KR KR1020187004571A patent/KR102825142B1/ko active Active
- 2016-07-13 PE PE2018000072A patent/PE20180741A1/es unknown
- 2016-07-13 EP EP26164394.4A patent/EP4732909A2/en active Pending
- 2016-07-13 IL IL297907A patent/IL297907B2/en unknown
- 2016-07-13 TN TNP/2018/000021A patent/TN2018000021A1/en unknown
- 2016-07-13 CR CR20180097A patent/CR20180097A/es unknown
- 2016-07-13 AU AU2016294417A patent/AU2016294417B2/en active Active
- 2016-07-13 IL IL256800A patent/IL256800B2/en unknown
- 2016-07-13 SG SG10201913431QA patent/SG10201913431QA/en unknown
- 2016-07-13 KR KR1020257020732A patent/KR20250099272A/ko active Pending
- 2016-07-13 MY MYPI2020006781A patent/MY203911A/en unknown
-
2018
- 2018-01-11 PH PH12018500098A patent/PH12018500098A1/en unknown
- 2018-01-12 DO DO2018000018A patent/DOP2018000018A/es unknown
- 2018-01-12 MX MX2023014921A patent/MX2023014921A/es unknown
- 2018-01-12 GT GT201800018A patent/GT201800018A/es unknown
- 2018-01-12 CL CL2018000103A patent/CL2018000103A1/es unknown
- 2018-02-09 EC ECIEPI20189949A patent/ECSP18009949A/es unknown
- 2018-02-12 CO CONC2018/0001363A patent/CO2018001363A2/es unknown
-
2020
- 2020-11-23 US US17/101,139 patent/US11596689B2/en active Active
-
2021
- 2021-01-13 JP JP2021003152A patent/JP2021063129A/ja active Pending
-
2022
- 2022-11-02 AU AU2022263520A patent/AU2022263520B2/en active Active
-
2023
- 2023-02-01 US US18/162,769 patent/US20240000929A1/en active Pending
- 2023-07-05 JP JP2023110414A patent/JP7605914B2/ja active Active
-
2024
- 2024-12-12 JP JP2024217195A patent/JP2025038055A/ja active Pending
-
2025
- 2025-09-05 AU AU2025226796A patent/AU2025226796A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7169389B2 (en) | Human CD154 binding molecules and treatment methods | |
| TWI889694B (zh) | 介白素-2藥劑及其用途 | |
| JP7267921B2 (ja) | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 | |
| ES2630328T3 (es) | Anticuerpos anti-OX40 y procedimientos de uso de los mismos | |
| US20080227704A1 (en) | CXCL13 binding proteins | |
| TWI496790B (zh) | 介白素-１３結合蛋白質 | |
| CN108367075B (zh) | 4-1bb结合蛋白及其用途 | |
| AU2013206788B2 (en) | Method of providing monoclonal auto-antibodies with desired specificity | |
| JP2022528927A5 (enExample) | ||
| AU2001248350A1 (en) | Antibodies to human CD154 | |
| JP2014516945A5 (enExample) | ||
| TW201031421A (en) | IL-1 binding proteins | |
| JP2020073499A (ja) | インターフェロンアルファ及びオメガ抗体アンタゴニスト | |
| JP2011520898A5 (enExample) | ||
| JP2022513434A5 (enExample) | ||
| JP2016527187A5 (enExample) | ||
| JP2013500721A5 (enExample) | ||
| JP2015504419A (ja) | Ｔ細胞反応の選択的阻害のための抗体および方法 | |
| JP2021063129A5 (enExample) | ||
| BR112013012396A2 (pt) | anticorpos anti-ccl20 de neutralização | |
| RU2010153580A (ru) | Иммуноглобулины с двумя вариабельными доменами и их применение | |
| RU2010153578A (ru) | Иммуноглобулины с двойными вариабельными доменами и их применение | |
| HK1207870A1 (en) | Anti-human sema4a antibodies useful to treat disease | |
| AU2021221123A1 (en) | Anti-BCMA therapy in autoimmune disorders | |
| TW202031685A (zh) | Ｌ ｉ ｌ ｒ ｂ ３ 結合分子及其用途 |